Pantoprazole Sodium Enteric-coated Capsules

This product is a proton pump inhibitor for gastric parietal cells. It is relatively stable under neutral and weakly acidic conditions and rapidly activated under strongly acidic conditions. Its pH-dependent activation characteristics make it more selective for H and K-ATPase. This product can specifically inhibit the H and K-ATPase on the secretory microtubules and tubular vesicles in the cytoplasm of the parietal cell apical membrane, causing irreversible inhibition of the enzyme, thereby effectively inhibiting the secretion of gastric acid. Since H and K-ATPase are the last process of acid secretion in parietal cells, this product has a strong acid-suppressing ability. It can not only non-competitively inhibit gastric acid secretion caused by gastrin, histamine, and choline, but also inhibit some basal gastric acid secretion that is not affected by choline or H2 receptor blockers. When used with other drugs, this product has the advantage of small drug interactions. This product is metabolized through the I system of the cytochrome P450 enzyme system in hepatocytes, and can also be metabolized through the II system. When used with other drugs that are metabolized by the P450 enzyme system, the metabolic pathway of this product can be carried out through the II enzyme system, which makes it less likely to have competitive effects on the drug-metabolizing enzyme system and reduce the interaction between drugs in the body. It has no mutagenic, carcinogenic and teratogenic effects.

The main ingredient of this product is pantoprazole sodium. Its chemical name is 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl-1H-benzoimidazole sodium salt monohydrate. Molecular formula: C16H14F2N3NaO4SH2O Molecular weight: 423.38

This product is a capsule containing white or off-white enteric-coated pellets.

Mainly used for: 1. Peptic ulcer bleeding. 2. Acute gastric mucosal damage caused by nonsteroidal anti-inflammatory drugs and the occurrence of ulcer bleeding under stress; 3. Preventing gastric acid reflux combined with aspiration pneumonia in patients after general anesthesia or major surgery and in weak and comatose patients.

This product must be taken under the guidance of a doctor according to the following dosage. Take one tablet orally before breakfast every day. The treatment course for duodenal ulcer is usually 2-4 weeks, and the treatment course for gastric ulcer and reflux esophagitis is usually 4 weeks. Please continue to take it if necessary. This product has small individual differences, and the dosage does not need to be adjusted for elderly patients.

Occasionally, dizziness, insomnia, drowsiness, nausea, diarrhea, constipation, rash and muscle pain may occur. Arrhythmia, increased aminotransferase, changes in renal function and decreased granulocytes may occur when used in large doses.

It is contraindicated for those who are allergic to this product; it is contraindicated for pregnant and lactating women.

Precautions for children: The efficacy and safety data of this product for children have not been established. It is forbidden for infants and young children. Precautions for pregnancy and lactation: It is forbidden for pregnant and lactating women. Precautions for the elderly: No dosage adjustment is required.

Not yet clear.

Keep sealed.

40mg (calculated as pantoprazole)

24 months

Nanjing CHANG AO Pharmaceutical Co., Ltd.

• Founded in:

  1997-08-13

• Address:

  No. 63, Kexin Road, Jiangbei New District, Nanjing

• Tax NO.:

  91320100634081762H

• Registered Funds:

  $46.83 million

• Website:

  Log in to view

• Email:

  Log in to view